Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults by Fo\ue0, Robin et al.
The new england  
journal of medicine
n engl j med 383;17 nejm.org October 22, 2020 1613
established in 1812 October 22, 2020 vol. 383 no. 17
From the Division of Hematology, De-
partment of Translational and Precision 
Medicine, Sapienza University of Rome 
(R.F., A.V., L.E., M.-C.P., M.C., M.-S.D.P., 
M.V., S.C.), Gruppo Italiano Malattie 
Ematologiche dell’Adulto (GIMEMA) Data 
Center, Fondazione GIMEMA Franco 
Mandelli Onlus (A.P., M.V.), and the De-
partment of Molecular Medicine, Sapien-
za University of Rome (A.G.), Rome, the 
Hematology Unit, Ospedale dell’Angelo 
and Ospedale SS Giovanni e Paolo, Venice 
(R.B., P.V., A.M.), the Division of Hema-
tology, Cardarelli Hospital, Naples (F. Fer-
rara), the Division of Hematology, Depart-
ment of Translational Medicine, University 
of Eastern Piedmont, Novara (M.L.), Di-
vision of Hematology and Bone Marrow 
Transplantation, Ospedali Riuniti Villa 
Sofia Cervello, Palermo (F. Fabbiano), the 
Department of Medicine, Section of Hema-
tology, University of Verona, Verona (M.B.), 
Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico di Milano, Università 
degli Studi di Milano (N.F.), and the De-
partment of Oncology–Hematology, Uni-
versity of Milan (A.R.), Milan, the Depart-
ment of Hematology, Ospedale Civile, 
Pescara (P.D.B.), and Azienda Socio-San-
itaria Territoriale Papa Giovanni XXIII, 
Bergamo (A.R.) — all in Italy. Address 
reprint requests to Dr. Foà at the Division 
of Hematology, Department of Transla-
tional and Precision Medicine, Sapienza 
University of Rome, Via Benevento 6, 00161 
Rome, Italy, or at  rfoa@ bce . uniroma1 . it.
*A complete list of the GIMEMA inves-
tigators is provided in the Supplemen-
tary Appendix, available at NEJM.org.
N Engl J Med 2020;383:1613-23.
DOI: 10.1056/NEJMoa2016272
Copyright © 2020 Massachusetts Medical Society.
BACKGROUND
Outcomes in patients with Philadelphia chromosome (Ph)–positive acute lympho-
blastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. 
Molecular remission is a primary goal of treatment.
METHODS
We conducted a phase 2 single-group trial of first-line therapy in adults with newly 
diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorti-
coids were administered, followed by two cycles of blinatumomab. The primary end 
point was a sustained molecular response in the bone marrow after this treatment.
RESULTS
Of the 63 patients (median age, 54 years; range, 24 to 82) who were enrolled, a 
complete remission was observed in 98%. At the end of dasatinib induction ther-
apy (day 85), 29% of the patients had a molecular response, and this percentage 
increased to 60% after two cycles of blinatumomab; the percentage of patients 
with a molecular response increased further after additional blinatumomab cycles. 
At a median follow-up of 18 months, overall survival was 95% and disease-free 
survival was 88%; disease-free survival was lower among patients who had an 
IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or 
both [i.e., IKZF1plus]). ABL1 mutations were detected in 6 patients who had increased 
minimal residual disease during induction therapy, and all these mutations were 
cleared by blinatumomab. Six relapses occurred. Overall, 21 adverse events of 
grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft, 
and 1 death was related to transplantation (4%).
CONCLUSIONS
A chemotherapy-free induction and consolidation first-line treatment with dasat-
inib and blinatumomab that was based on a targeted and immunotherapeutic 
strategy was associated with high incidences of molecular response and survival 
and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded 
by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 
D-ALBA EudraCT number, 2016 - 001083 - 11; ClinicalTrials.gov number, NCT02744768.)
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The prognosis in adults with Phila-delphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) has mark-
edly improved since the advent of ABL-specific 
tyrosine kinase inhibitors. The use of these 
agents, with or without systemic chemotherapy, 
allows most patients to have a complete hema-
tologic response.1-15 Over the past 15 years, the 
GIMEMA (Gruppo Italiano Malattie Ematologiche 
dell’Adulto) cooperative trial group has adopted 
a chemotherapy-free induction strategy involving 
prephase treatment with glucocorticoids for a 
7-day period, during which all the patients who 
are enrolled in the ALL trials are centrally evalu-
ated for the presence or absence of the BCR-ABL1 
gene fusion. Patients with Ph-positive ALL then 
undergo an induction phase involving the use of 
a tyrosine kinase inhibitor (plus glucocorticoids) 
and central nervous system (CNS) prophylaxis but 
no systemic chemotherapy.16-19 This treatment has 
resulted in a complete hematologic response in 
94 to 100% of patients, irrespective of age, and 
virtually no deaths during the induction phase.
In ALL, the achievement of a profound and 
sustained decrease in minimal residual disease 
is associated with an increased chance of cure. 
In clinical trials of first-line treatment for pa-
tients with ALL of all ages for whom the goal is 
a decreased likelihood of relapse, the primary 
end point is a reduction in the tumor burden to 
less than 1 tumor cell in 10,000 bone marrow 
mononuclear cells.
In the phase 2, single-group GIMEMA LAL2116 
D-ALBA trial of first-line treatment in adults 
(with no upper age limit) who had newly diag-
nosed Ph-positive ALL, dasatinib induction was 
followed by consolidation with the bispecific 
anti-CD3 and anti-CD19 monoclonal antibody 
blinatumomab.20 Dasatinib, a second-generation 
inhibitor of the ABL tyrosine kinase, is more 
potent than imatinib. The bifunctional antibody 
was designed to activate T cells with its anti-CD3 
group and bind to tumor cells with its anti-CD19 
group to promote cellular cytotoxicity.
Me thods
Trial Design and End Points
The design of the trial is shown in Figure S1 and 
detailed in the Supplementary Methods section, 
both in the Supplementary Appendix (available 
with the full text of this article at NEJM.org). 
Before the patients received dasatinib, they re-
ceived prephase treatment with a glucocorticoid 
for 7 days. Glucocorticoids were continued for 
24 more days and discontinued on day 31. Dasati-
nib (at a dose of 140 mg once daily) was admin-
istered as induction therapy for 85 days. All the 
patients who completed the induction phase re-
ceived postinduction consolidation treatment with 
blinatumomab at a dose of 28 μg per day; before 
each blinatumomab cycle, dexamethasone (at a 
dose of 20 mg) was administered. To prevent 
CNS adverse events, levetiracetam (at a dose of 
500 mg twice daily) was administered. A mini-
mum of two cycles was mandatory; up to three 
additional cycles were allowed. Dasatinib was 
continued during treatment with blinatumomab 
and after the administration of blinatumomab, 
except in a few patients in whom a T315I muta-
tion was detected during the induction phase.
CNS lumbar punctures were performed at 
diagnosis, at days 14, 22, 43, 57, and 85, and at 
the end of each blinatumomab cycle, for a total 
of 12 procedures. The choice of postconsolida-
tion treatment, including allogeneic hematopoi-
etic stem-cell transplantation and subsequent ad-
ministration of a tyrosine kinase inhibitor, was 
made by the investigators. Data on follow-up 
and treatment after blinatumomab consolida-
tion are being collected in an ancillary trial 
(GIMEMA LAL2217; ClinicalTrials.gov number, 
NCT03318770).
The primary end point of our trial was a mo-
lecular response (a complete molecular response 
and a positive nonquantifiable response [i.e., 
minimal residual disease–positive samples out-
side the quantitative range]) with induction ther-
apy involving dasatinib plus glucocorticoids fol-
lowed by two cycles of blinatumomab. The 
secondary end points were a decreased level of 
minimal residual disease associated with blina-
tumomab; disease-free survival, overall survival, 
and the cumulative incidence of relapse; the safety 
profile of dasatinib–blinatumomab; and the mo-
lecular response and overall and disease-free 
survival according to the molecular characteris-
tics at baseline, including the type of fusion 
protein (190-kd fusion protein [p190] or 210-kd 
fusion protein [p210]) and the presence or ab-
sence of additional genomic lesions. Transla-
tional research end points included an analysis 
of copy-number aberrations, screening for ABL1 
mutations in patients who had an increase in 
A Quick Take 
is available at 
NEJM.org
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minimal residual disease, and monitoring of the 
host immunologic compartment.
Assessments
Assessment of Hematologic Response
A complete hematologic response was defined as 
5% bone marrow blasts or less, the absence of 
blasts in the peripheral blood, no extramedullary 
involvement, and a full recovery of the peripheral-
blood count (i.e., a neutrophil count of >1500 
cells per cubic millimeter and a platelet count of 
>100,000 per cubic millimeter). Hematologic re-
lapse was defined as the presence of blasts in the 
peripheral blood or in any non hematologic site, 
or at least 5% bone marrow blasts.
Molecular Analysis and Molecular Response
Molecular analyses of bone marrow samples 
were performed at a central laboratory. At diag-
nosis, a multiplex reverse-transcriptase–poly-
merase-chain-reaction (RT-PCR) assay21 was used 
to detect the p190 or p210 forms of the BCR-ABL1 
fusion product during prephase treatment with 
glucocorticoids. Monitoring of minimal residual 
disease with quantitative RT-PCR was performed 
at days 22, 45, 57, and 85 of induction therapy 
and at the end of each blinatumomab cycle. The 
number of BCR-ABL1 copies and the interpreta-
tion of results were determined according to the 
European Study Group on MRD [minimal re-
sidual disease] Detection in ALL (EuroMRD).22,23
A complete molecular response was defined 
as a ratio of BCR-ABL1 to ABL1 of 0. A positive 
nonquantifiable response was defined according 
to the new EuroMRD guidelines23; both a com-
plete molecular response and a positive non-
quantifiable response were considered to be evi-
dence of a molecular response. A molecular 
relapse was defined as a 2-log or greater increase 
in minimal residual disease measured with the 
use of quantitative RT-PCR.
ABL1 Mutational Screening and Copy-Number 
Aberration Analysis
ABL1 mutations were evaluated by means of 
Sanger sequencing in patients who had an in-
crease in minimal residual disease. We used the 
SALSA MLPA Probemix P335 ALL-IKZF1 kit (MRC 
Holland) to evaluate recurrent deletions in diag-
nostic genomic DNA in 46 patients for whom 
genomic material was available. The assay is de-
scribed by Fedullo et al.24 The product of IKZF1, 
the Ikaros gene, is involved in chromatin re-
modeling and alteration of gene expression, 
and deletions of IKZF1 are common in patients 
with ALL.25
Host Immunologic Compartment
Peripheral-blood mononuclear cells were ob-
tained after centrifugation with Ficoll–Histo-
paque (Axis-Shield). The distribution of CD4+ 
T cells, CD8+ T cells, natural killer cells, natural 
killer T cells, and regulatory T cells (Tregs) was 
analyzed by means of direct immunofluores-
cence to assess immunologic changes after treat-
ment with blinatumomab, as described by Duell 
and colleagues.26
Trial Oversight
The trial was designed by GIMEMA, in collabo-
ration with the academic authors. The trial was 
approved by the ethics committee at each partici-
pating center and was conducted in accordance 
with the Good Clinical Practice guidelines of the 
International Council for Harmonisation and 
the provisions of the Declaration of Helsinki. All 
the patients provided written informed consent. 
Data were collected by the trial investigators and 
staff members and analyzed by GIMEMA. All the 
authors interpreted the data, collaborated in the 
preparation of the manuscript and in the deci-
sion to submit it for publication, and vouch for 
the accuracy and completeness of the data and 
for the fidelity of the trial to the protocol (avail-
able at NEJM.org). All the authors, their institu-
tions, and GIMEMA were required to maintain 
data confidentiality during the trial.
Statistical Analysis
The trial was designed to evaluate the activity of 
dasatinib plus blinatumomab in inducing a mo-
lecular response in adults with Ph-positive ALL. 
Consideration was given to reject the null hypoth-
esis, which was based on data on the historical 
control group in the GIMEMA LAL1509 trial19 
— that 40% of the patients who received dasati-
nib plus blinatumomab would have a response 
— as compared with the alternative hypothesis, 
fixed at 60% of the patients, with 90% power 
and a 5% significance level with a single-stage 
phase 2 design.
Estimates of median disease-free and overall 
survival were calculated with the use of the re-
verse Kaplan–Meier method, and the distribution 
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of time-to-event end points was calculated with 
the Kaplan–Meier method. Overall survival was 
calculated from the date of the initiation of 
treatment to death from any cause, and disease-
free survival and the cumulative incidence of 
relapse were calculated from the end of induc-
tion therapy (day 85) for patients having a com-
plete hematologic response to hematologic re-
lapse. The cumulative incidence of relapse was 
calculated with the cumulative incidence meth-
od, with death in patients who had a complete 
hematologic response as a competing risk.
Differences between the groups were ana-
lyzed with the use of two-sided log-rank tests. 
Kaplan–Meier estimates at 1 year with 95% con-
fidence intervals are reported. Hazard ratios 
with 95% confidence intervals were estimated 
with the Cox proportional model. The 95% con-
fidence intervals were not adjusted for multiple 
comparisons and should not be used to infer 
definitive treatment effects.27,28
R esult s
Characteristics of the Patients
Between May 9, 2017, and January 9, 2019, a to-
tal of 63 adults with newly diagnosed Ph-positive 
ALL were enrolled (Table 1). The median age was 
54 years (range, 24 to 82), 54% of the patients 
were women, and the median white-cell count 
was 13,000 per cubic millimeter (range, 600 to 
88,000).
A total of 41 patients had the p190 fusion 
protein, 17 had the p210 fusion protein, and 
5 had both; for all analyses, the latter two sub-
groups were considered together. Copy-number 
analysis showed that the IKZF1 deletion was the 
most frequent aberration (in 25 of 46 patients 
[54%]); other aberrations involved CDKN2A or 
CDKN2B (in 13 patients [28%]), PAX5 (in 10 pa-
tients [22%]), RB1 (in 6 patients [13%]), and 
EBF1 (in 5 patients [11%]). A total of 11 of 46 
patients (24%) were classified as having IKZF1plus 
(i.e., IKZF1 associated with PAX5 deletions, CDKN2A 
or CDKN2B deletions, or both) (Fig. S2).
Response to Treatment
A total of 61 patients completed induction with 
dasatinib. A 73-year-old woman withdrew from 
the trial because of toxic effects after she re-
ceived dasatinib for 10 days and she later died of 
pneumonia, and an 82-year-old woman with-
drew from the trial because of pneumonia and 
pneumonitis that occurred while she had a com-
plete hematologic response.
At the end of the induction phase (day 85), 
98% of the patients (62 of 63 patients) had a 
complete hematologic response, including the 
patient in complete hematologic response who 
withdrew from the trial; 29% (17 of 59 patients) 
had a molecular response. Overall, no significant 
differences in molecular response were noted 
between patients with p190 rearrangement prod-
ucts and those with p210 rearrangement products 
(32% and 24%, respectively), even though a faster 
molecular clearance was observed in patients 
with p190 than in those with p210 (Fig. S3). The 
number of patients with a molecular response 
after induction therapy was lower among those 
with IKZF1plus (1 of 11 patients) than among 
those with IKZF1 alone and among those with no 
deletions (9 of 33 patients).
Of the 61 patients who completed the induc-
tion phase, 58 received one cycle of blinatumo-
mab, 56 received two cycles, 45 received three 
cycles, 37 received four cycles, and 29 received 
five cycles (Fig. 1). The median time from the 
end of induction therapy to the start of blina-
tumomab was 10 days (range, 7 to 41). At the 
end of the second cycle of blinatumomab, 60% 
of the patients (33 of 55 patients) had a molecu-
lar response. In the intention-to-treat population 
Table 1. Demographic and Clinical Characteristics  







Sex — no. (%)
Male 29 (46)
Female 34 (54)
White-cell count — per mm3
Median 13,000
Range 600–88,000
Fusion protein — no. (%)
p190 41 (65)
p210 17 (27)
p190 and p210 5 (8)
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(all the patients who entered the trial), 52% of 
the patients had a molecular response. The per-
centages of patients with a molecular response 
further increased after subsequent cycles of 
blinatumomab — to 70% (28 of 40 patients) 
after the third cycle, 81% (29 of 36 patients) af-
ter the fourth cycle, and 72% (21 of 29 patients) 
after the fifth cycle (Table 2).
After two cycles of blinatumomab, no signifi-
cant differences were noted between patients 
with p190 and those with p210 with respect to 
a molecular response; similarly, there were no 
significant differences between patients with 
IKZF1plus and those with IKZF1 alone or with no 
IKZF1 deletions after the administration of blina-
tumomab.
Survival
The median follow-up was 18 months (range, 1 to 
25). Overall survival was 95% (95% confidence 
interval [CI], 90 to 100) (Fig. 2A), and disease-free 
survival was 88% (95% CI, 80 to 97) (Fig. 2B). 
The probability of disease-free survival among 
patients who had a molecular response at the 
end of induction therapy (day 85) was 100%, as 
compared with 85% among patients with a non-
molecular response (Fig. S4A). No significant 
differences with respect to disease-free survival 
were observed between patients with p190 (85%; 
95% CI, 74 to 97) and those with p210 (95%; 
95% CI, 86 to 100) (Fig. S4B). Inferior disease-
free survival was observed among patients with 
IKZF1plus deletions: disease-free survival among 
patients with no IKZF1 deletions, IKZF1 deletions 
alone, or IKZF1plus deletions was 100% (95% CI, 
100 to 100), 92% (95% CI, 79 to 100), and 64% 
(95% CI, 41 to 100), respectively (Fig. 3A). Simi-
larly, overall survival was inferior among patients 
with IKZF1plus deletions (100% among patients 
with no IKZF1 deletions, 93% among those with 
IKZF1 deletions alone, and 82% among those 
with IKZF1plus deletions) (Fig. 3B).
ABL1 Mutations and Genomic Aberrations
An ABL1 mutational analysis was carried out in 
15 patients who had evidence of an increase in 
minimal residual disease during the induction 
phase and in 1 patient who had an overt relapse. 
Of the 15 patients with minimal residual dis-
ease, 8 had wild-type disease, whereas muta-
tions were detected in 7 patients (6 with T315I 
and 1 with E255K). All but one of the mutations 
occurred between day 57 and 85 (the end of in-
duction therapy), before the initiation of blina-
tumomab, and all the mutations were cleared by 
blinatumomab. The only patient who was evalu-
ated at relapse had a T315I mutation. A T315I 
mutation developed in 4 of the 11 patients with 
IKZF1plus (36%).
Relapses and Death
Overall, six relapses occurred. Three relapses 
were hematologic; one occurred in a patient with 
a major protocol violation (a delay in administra-
tion of blinatumomab of >2 months), one oc-
curred after 12 months in the patient who dis-
continued the trial after receiving dasatinib for 
12 days, and one occurred in a patient after the 
second cycle of blinatumomab. Two relapses were 
isolated in the CNS, and one relapse was nodal 
(Fig. 1). The cumulative incidence of relapse in 
the whole population was 8% (95% CI, 8 to 8) 
(Fig. 2C). At diagnosis, three of four patients 
with relapse had IKZF1plus aberrations and one 
had an isolated IKZF1 aberration; furthermore, 
five of six patients had a T315I mutation. As 
expected, the cumulative incidence of relapse 
was higher among patients with IKZF1plus dele-
tions (27%; 95% CI, 23 to 31) than among those 
with no IKZF1 deletions (0%; 95% CI, 0 to 0) or 
among those with IKZF1 deletions alone (8%; 
95% CI, 6 to 9) (Fig. 3C). CD19+ expression was 
evaluated in five patients with relapse, and all 
were CD19+.
Four deaths occurred. A 73-year-old woman 
died from progression of pneumonia during 
the induction phase, two patients with a first 
complete hematologic response died (one patient 
with a mechanical aortic valve died from endo-
carditis, and one patient died from a veno-occlu-
sive disorder after allogeneic stem-cell trans-
plantation), and one patient with a second 
complete hematologic response died from dis-
ease progression after allogeneic stem-cell trans-
plantation.
Toxic Effects
Overall, 60 adverse events occurred in 28 patients 
(Table S2). Adverse events of grade 3 or higher 
were cytomegalovirus (CMV) reactivation or in-
fection (in 6 patients), neutropenia (in 4 patients), 
persistent fever (in 2 patients), pleural effusion 
(in 1 patient), pulmonary hypertension (in 1 pa-
tient), and a neurologic disorder (in 1 patient).
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Figure 1. Enrollment and Outcomes.
Treatment was ongoing in one patient. CNS denotes central nervous system.
63 Patients began to receive
induction therapy
1 Withdrew from trial because
of toxic effects (age, 73 yr)
1 Died from progression
of pneumonia
61 Completed induction therapy
at day 85 
2 Withdrew from trial because
of toxic effects
1 Had hematologic relapse
(protocol violation)
1 Died from endocarditis
1 Withdrew from trial
(in complete hematologic
response after receiving
dasatinib for 12 days)
(age, 82 yr)
1 Had hematologic relapse
12 mo after diagnosis
1 Withdrew from trial because
of medical decision
1 Had nodal relapse
1 Underwent allogeneic
stem-cell transplantation
after withdrawing from trial
7 Completed therapy
58 Completed cycle 1
of blinatumomab 
9 Completed therapy
1 Had hematologic relapse
1 Had CNS relapse
















45 Completed cycle 3
of blinatumomab




1 Died from veno-occlusive
disease
29 Completed cycle 5
of blinatumomab
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Transplantation
Of the 24 patients (median age, 52 years; range, 
24 to 67) who received allografts, 23 received an 
allograft during the first complete hematologic 
response and 1 received an allograft during the 
second complete hematologic response (Fig. 1). 
Seven patients received an allograft from a sib-
ling, 12 from an unrelated donor, and 5 from a 
haploidentical donor. Of the patients who under-
went transplantation during the first complete 
hematologic response, 17 (74%) had minimal 
residual disease at the end of induction therapy 
and 6 had a molecular response; after two cycles 
of blinatumomab, 11 patients still had minimal 
residual disease. Fourteen patients had no graft-
versus-host disease (GVHD), 9 had acute GVHD, 
and 1 had chronic GVHD. Of the 23 patients 
who underwent transplantation during the first 
complete hematologic response, 5 patients had 
received ponatinib and 1 had received a cycle of 
chemotherapy before transplantation, whereas 
the remaining 17 (74%) underwent the alloge-
neic hematopoietic stem-cell transplantation 
directly. Two deaths occurred (one from relapse 
and one from veno-occlusive disorder). The 
transplantation-related mortality was 4%.
Host Immunologic Compartment
Longitudinal time points could be evaluated after 
the initiation of blinatumomab in 17 patients. A 
decrease in the percentage of Tregs was ob-
served in patients who had received the third 
cycle of blinatumomab, and this decrease was 
maintained after the fourth cycle and after the 
fifth cycle (Fig. S5). Similarly, the ratio of CD4+ 
to CD8+ T cells decreased over time, sustained 
by an increase in the median percentage of 
CD8+ T cells after the fourth cycle of blinatum-
omab and a small decrease in CD4+ T cells.
Discussion
In our phase 2 trial, adults with newly diagnosed 
Ph-positive ALL received first-line treatment in-
volving induction with dasatinib followed by con-
solidation with blinatumomab. The first analysis 
of the trial showed that this chemotherapy-free 
induction and consolidation strategy was feasible 
and safe, with only one death in the induction–
consolidation period. In addition, there was a 
high incidence of molecular response (the pri-
mary end point), and the percentages of patients 
with a molecular response increased further with 
more cycles of blinatumomab. The data on over-
all and disease-free survival are promising, and 
no relapses were observed during induction and 
consolidation therapy. The responses were less 
favorable in patients with IKZF1plus than in those 
with IKZF1 alone or in those with no deletions. 
Blinatumomab was active on minimal residual 











number of patients/total number (percent)
Induction period
Day 22 48/58 (83) 3/58 (5) 7/58 (12) 10/58 (17)
Day 45 43/60 (72) 9/60 (15) 8/60 (13) 17/60 (28)
Day 57 38/56 (68) 11/56 (20) 7/56 (12) 18/56 (32)
Day 85 42/59 (71) 6/59 (10) 11/59 (19) 17/59 (29)
Blinatumomab cycle
After cycle 1 20/55 (36) 19/55 (35) 16/55 (29) 35/55 (64)
After cycle 2 22/55 (40) 23/55 (42) 10/55 (18) 33/55 (60)
After cycle 3 12/40 (30) 20/40 (50) 8/40 (20) 28/40 (70)
After cycle 4 7/36 (19) 17/36 (47) 12/36 (33) 29/36 (81)
After cycle 5 8/29 (28) 16/29 (55) 5/29 (17) 21/29 (72)
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disease–positive cells carrying the ABL1 mutation. 
Allotransplants in patients who had not received 
systemic chemotherapy were associated with a 
very low transplantation-related mortality.
The patient outcomes were excellent, regard-
less of age, as indicated by the very low mortality. 
Unexpectedly, one of the most common adverse 
events was CMV reactivation. This phenomenon 
has been previously reported in patients who 
have received dasatinib.29-31 After the second cy-
cle of blinatumomab, 60% of the patients with 
data that could be evaluated had a molecular 
response; this percentage increased further (up 
to 81%) with additional cycles of blinatumomab; 
this finding suggests that as first-line treatment 
and in patients who had not received chemo-
therapy, blinatumomab was more active than pre-
viously reported. As a result of the high molecular 
response, overall survival was 95% and disease-
free survival was 88% at a median follow-up of 
18 months. These results compare favorably with 
those in other clinical trials, including those 
involving the use of ponatinib (a third-genera-
tion ABL inhibitor with activity against the main 
ABL resistance alteration, T315I, but with great-
er toxicity than dasatinib) with or without che-
motherapy. In the first report of a trial conducted 
by Jabbour and colleagues,32 among patients 
who received a combination of ponatinib and 
hyper-CVAD (hyperfractionated cyclophospha-
mide, vincristine, doxorubicin, and dexametha-
sone), the progression-free survival at 1 year was 
96% and overall survival at 1 year was 86%. In a 
follow-up analysis, event-free and overall sur-
vival at 2 years were 81% and 80%, respectively; 
the combination was associated with notable 
(mainly cardiovascular) toxic effects, which led 
to substantial modifications to the regimen.33 
Similarly, in the GIMEMA LAL1811 trial34 involv-
ing younger patients with coexisting conditions 
and elderly patients, the overall survival at 1 year 
among patients who received ponatinib alone 
was 87.5%.
In the current trial, among patients who had 
a molecular response at the end of induction and 
consolidation therapy, the probability of disease-
free survival was 100%, as compared with 85% 
among those with minimal residual disease. No 
significant difference in survival was seen be-
Figure 2. Overall Survival, Disease-free Survival, and Cumulative Incidence 
of Relapse.
Shown are the percentages of all patients with overall survival (Panel A), 
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tween patients with p190 and those with p210. 
The presence of additional genomic lesions (i.e., 
in patients with IKZF1plus) had an effect on dis-
ease-free survival (100% among patients with no 
lesions, 92% among those with IKZF1 deletions 
alone, and 64% among those with IKZF1plus). 
These findings underscore those from previous 
trials.24,25,35 The effect of additional genomic le-
sions was less evident with respect to overall 
survival (100% among patients with no IKZF1 
deletions, 93% among those with IKZF1 dele-
tions alone, and 82% among those with IKZF1plus 
deletions), which indicates that treatment inten-
sification with blinatumomab might reduce the 
negative prognostic effect of this genotype. In 
the previous GIMEMA LAL1509 trial,19 all pa-
tients with IKZF1plus had disease relapse within 
24 months; although a formal comparison can-
not be carried out, we found a marked improve-
ment in disease-free survival with the dasatinib–
blinatumomab combination.
One major problem is presented by the devel-
opment of ABL1 mutations — particularly the 
gatekeeper T315I — on minimal residual dis-
ease–positive cells. All the mutations that oc-
curred during induction (between days 57 and 
85 of the induction phase) were cleared by blina-
tumomab. In 2 patients, a rapid therapeutic in-
tervention (i.e., a switch to ponatinib and trans-
plantation) prevented an overt relapse. A total of 
11 patients were considered to have IKZF1plus, and 
a T315I mutation developed in 4 of them. This 
observation strongly suggests that the IKZF1plus 
phenotype is associated with a status of genomic 
instability that facilitates the acquisition of delete-
rious mutations.
Of the 24 patients who underwent transplan-
tation, 2 died. Despite a median age of 52 years 
(range, 24 to 67), only 1 patient had a transplan-
tation-related death, so the transplantation-related 
mortality was 4%, which is markedly lower than 
Figure 3. Disease-free Survival, Overall Survival,  
and Cumulative Incidence of Relapse, According  
to the Presence or Absence of IKZF1 or IKZF1plus  
Deletions.
Shown are the percentages of patients with disease-
free survival (Panel A), overall survival (Panel B), and 
relapse (Panel C), according to the absence of IKZF1 
deletions, the presence of IKZF1 deletions alone, or 





























































































































C Cumulative Incidence of Relapse
No IKZF1 IKZF1 alone IKZF1plus
The New England Journal of Medicine 
Downloaded from nejm.org by GIULIO DALFONSO on October 22, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;17 nejm.org October 22, 20201622
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
that reported in previous studies. It is possible 
that patients who have not received systemic 
chemotherapy are less prone to serious trans-
plantation-related complications than those who 
have received systemic chemotherapy. The other 
patient who died had undergone transplantation 
with a second complete hematologic response 
and died from disease recurrence.
In our trial, we investigated the host immuno-
logic compartment in 17 patients, and we found 
a decrease in Tregs starting from the third cycle 
of blinatumomab onward and an increase in 
CD8+ cells beginning after the fourth cycle of 
blinatumomab. Duell and colleagues26 have re-
ported that the percentage of Tregs was inversely 
correlated with response. Overall, these findings 
suggest that in patients with newly diagnosed, 
Ph-positive ALL who have not received chemo-
therapy, an immunotherapeutic effect on the 
host immune system is widely observed.
In this trial, adult patients with Ph-positive 
ALL had a benefit from a chemotherapy-free in-
duction and consolidation strategy with dasat-
inib followed by blinatumomab. This combina-
tion was associated with high incidences of 
complete hematologic response and molecular re-
sponse and with impressive survival at 18 months.
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